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Lupus nephropathy in New Zealand F! hybrid mice treated by (—)15-
deoxyspergualin. The effect of (—)15-deoxyspergualin (15-dsp), a new
immunosuppressant which was originally separated from the culture
filtrate of a strain of Bacillus laterosporus, was evaluated in this study.
Various doses of 15-dsp were subcutaneously administered to New
Zealand black/white Fl hybrid mice (B/WF1) four times a week starting
at 14 weeks of age, just prior to the onset of nephropathy. The life span
of the treated animals, studied at 0.6 to 6.0 mg/kg body weights,
compared with the control mice was significantly prolonged by 15-dsp
treatment (percent survival of the treated mice at 50 to 70 weeks of age
was significantly higher than that of the control mice, except that of the
0.6 mg group at 60 wks of age, P < 0.05 by Fisher's exact test). In the
6.0 mg group of mice, complete suppression of spontaneously progres-
sive splenomegaly with decreased total spleen cells was observed at 24
through 36 weeks of age compared with the same-aged control group of
mice (P < 0.01). Absolute numbers of L3T4+ splenocytes determined
by flow cytometry, as well as L3T4+/Lyt2+ ratio, were decreased,
while in vitro interleukin 2 production by splenocytes induced with
staphylococcal enterotoxin A was significantly enhanced. Serum IgG
anti-ds DNA antibody levels, measured by radioimmunoassay in the
treated mice, were significantly lower at 24 through 36 weeks of age
than those in the control mice (P < 0.01), and the incidence of
significant proteinuria (l00 mg/dl) in the 15-dsp group was lower at
both 32 and 36 weeks of age (P < 0.001). Glomerular histological score
by light microscopy and IgG and C3 deposition determined by immu-
nofluorescence were clearly improved by the 15-dsp treatment at 24 to
36 weeks of age. From these data we may conclude that 15-dsp
effectively suppressed the spontaneous polyclonal B cell activation
inherent to these lupus prone mice, leading to decreased anti-DNA
production and inhibition of subsequent development of nephropathy.
Although administration of its high dose causes bone marrow suppres-
sion, 15-dsp, which is devoid of known nephrotoxicity, may deserve
further evaluation as one of the promising therapeutic agents for
glomerulonephritis.
Prognosis of lupus nephropathy has been improved since the
advent of immunosuppressants into the therapeutic regimen.
Since the classical drugs in clinical use, such as prednisone,
azathioprine and cyclophosphamide, are not free of significant
complications [1], search for new medications, like cyclosporin
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A [2, 3], cyclophosphazene derivative [4], or mizoribine [5], has
been done using murine models of the disease. Although
cyclosporin A has been thought to selectively suppress helper
T-cell function by modulating lymphokine production while
sparing suppressor function [6], nephrotoxicity of the agent has
proven to be one of the major problems in renal transplant
patients [7].
Spergualin, a new antibiotic, which was shown to have an
antitumor activity against mouse L-1210 leukemia, was discov-
ered in culture filtrates of a strain of Bacillus laterosporus,
BMG162-aF2 [8]. Its structure was determined [9], and it was
then totally synthesized [10]. One of its derivatives, (—)15-
deoxyspergualin (15-dsp), whose structure was determined to
be (—)-(1SS)-1 -amino-i 9-guanidino-1 1 -hydroxy-4,9, 12-triazano-
nadecane-1O,13-dione [11], was found to be effective for adju-
vant arthritis and experimental allergic encephalitis in rats [121,
and to suppress anti-SRBC antibody production in mice [13].
Although some degree of subacute hepatotoxicity and bone
marrow suppression was observed in rats and dogs given a high
doses of the drug (Aoyagi T: unpublished observations), no
nephrotoxicity due to 15-dsp was reported. The present study
was designed to investigate the immunosuppressive effect of
15-dsp on experimental lupus nephropathy in New Zealand
black/white Fl hybrid mice (B/WFI). 15-Dsp therapy, which
was begun just prior to the onset of the nephropathy, was
shown to significantly prolong the life span by totally suppress-
ing the development of the renal disease in these animals.
Methods
Mice
Four-week-old female B/WF1 mice were purchased from
Charles River Japan, Inc. (Atsugi, Japan), and were maintained
at our mouse unit until studied.
Study protocol
Survival of mice. Ten mice were given, s.c., 50 d of
phosphate buffered saline (PBS, pH 7.2) every, other day
starting at 14 weeks. These animals were weighed every two
weeks and kept up to their natural death to determine the life
span in 15-dsp-untreated B/WF1 mice. An additional 42 mice
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were divided into four groups, and these groups of mice were
administered 0.6, 1.5, 3.0 or 6.0 mg per kg body weight of
15-dsp dissolved in 50 l of PBS according to the same schedule
as in the control mice.
Sequential effect of 15-dsp on spleen cell function, on serum
anti-DNA antibody, and on renal histology. After collecting
urine, 10 14-week-old non-treated mice were sacrificed by
decapitation. Blood was obtained to separate serum, which was
kept in aliquots at —80°C for the measurement of antibody to
double stranded deoxyribonucleic acid (ds-DNA). Spleens were
taken aseptically for the following study, and the kidneys were
processed for light microscopy and immunofluorescence study.
Additionally, 90 14-week-old mice were put on treatment with
either PBS or 15-dsp, 6 mg per kg, following the same protocol
as described above. They were divided into five groups of 20
mice, each comprising 10 PBS-treated animals and 10 15-dsp-
treated ones. They were sacrificed at 20, 24, 28, 32 or 36 weeks
of age, and their spleens and kidneys were processed as above.
Flow cytometry
Single spleen cell suspension was obtained by pressing the
spleen with forceps into pieces in 10 ml cold, Hanks balanced
salt solution (HBSS, pH 7.3) and filtering them through stain-
less steel mesh. After lysing the red blood cells with 0.83%
NH4CI-Tris buffer, the cells were washed three times with cold
HBSS with 3% fetal calf serum (FCS). Twenty-five microliters
of rat anti-mouse L3T4 (Clone YTS 191.1, Sera-Lab, UK) or
anti-mouse Lyt 2 (Clone YTS 169.4) was added to 1 x 106 cells
suspended in 50 s1 PBS. After being incubated at 0°C for 30
minutes, they were washed with PBS with 0.1% Na3N, and
were further incubated with 50 l fluorescein isothiocyanate
(FITC)-conjugated goat anti-rat IgG (Cappel Laboratories,
Cochranville, Pennsylvania, USA) at 0°C for 30 minutes. They
were then washed and suspended in one ml of 0.1% Na3N PBS.
After being filtered through 45 m nylon mesh, they were flow
cytometrically analyzed with EPICS V (Coulter Electronics,
Hialeah, Florida, USA).
Interleukin 2 (IL-2) production
IL-2 was produced and assayed according to the protocol
previously reported [14, 15]. In brief, 5 X 106 spleen cells were
suspended in two ml of RPMI 1640 (Difco Laboratories, De-
troit, Michigan, USA) with 5% FCS (lot No. 6140, Flow
Laboratories, Stanmore, N.S.W., Australia), 2 mi 1-glutamine,
5 X l0 M 2-ME, 100 U/mi penicillin and 100 g/ml strepto-
mycin. They were incubated with 10 ng/ml of staphylococcal
enterotoxin A(Ent A; from Dr. H. Igarashi, Tokyo Metropoli-
tan Research Institute of Hygiene, Tokyo) at 37°C in 5% CO2 in
air for 48 hours. Ent A has been shown to be one of the most
potent T-cell activating agents [14, 15, manuscript in prepara-
tioni. The supernatant was harvested and stored at —20°C in
aliquots until being assayed for the IL-2 activity.
IL-2 assay
Complete Click's solution with 10% FCS, 2 m glutamine, 5
x i0 M 2-ME, 0.18% NaHCO3, and antibiotics was used to
dilute the specimen and also for the cell culture. One hundred i.d
of the Ent A culture supernatant was put in 96-well round-
bottomed microtiter plate (Nunc, Roskilde, Denmark) in tripli-
cates, and was serially diluted with Click's media. One hundred
.d of IL-2-dependent CTLL cells, 3 x i0 cells/mi, was added
to each well, and they were incubated for 20 hours. Then they
were pulse-labeled with one pCi of 3H-thymidine (3H-TdR, 20
mCi/mM, Radiochemical Centre, Amersham, UK) for four
hours, and the 3H-TdR uptake was measured with a scintillation
counter (Mark III, Searle Analytic, Des Plaines, Illinois, USA).
The amount of IL-2 generated in the supernatant was calculated
with probit analysis, and was expressed as U/ml of a standard
IL-2 specimen (recombinant human IL-2, i0 U/mi, Shionogi
Pharmaceuticals Co., Tokyo).
Measurement of serum anti-DNA antibody
The measurement of IgG anti-dsDNA antibody was per-
formed by the solid-phase radioimmunoassay of Sekigawa et al
[161. Round-bottomed row/8U-weils (M1748A, Dynatech Lab-
oratories, Plochingen, FRG) was successively coated with
0.001% protamine sulfate and dsDNA. dsDNA was prepared by
digesting calf thymus DNA (Sigma Chemical, St. Louis, Mis-
souri, USA) with Si nuclease (Seikagaku Kogyo, Tokyo,
Japan) and fractionating on a hydroxyapatite column. Fifty
microliters of appropriately-diluted test sera were added to the
microplate, which was left at room temperature for two hours.
After washing five times, '251-labelled rabbit anti-mouse y chain
(Cappel Laboratories) was added. The plate was further washed
for three times and the radioactivity determined by a well-type
counter.
Renal histology
Light microscopic and immunofluorescent changes were
semi-quantitatively evaluated according to the following scor-
ing system. Uncoded specimens were separately studied by
three of us (KI, KK and YM) who had no prior knowledge of
the pertinent data. Most of the time the scores obtained
conformed among the three. But on rare occasions when they
were discordant, the lowest of the three scores was considered
for the control mice and the highest for the treated to eliminate
potential bias.
Light microscopy. The details were previously reported [5].
One to 3 p-thick sections were prepared from 10% buffered
formalin-fixed specimen. Histological findings of glomeruli
stained with hematoxylin-eosin or with periodic acid Schiff
(PAS) were evaluated by three parameters: intracapiilary pro-
liferation, extracapiilary proliferation and tuft necrosis with
thickening of capillary walls. The degree of intensity or extent
of the above three lesions were each graded from 0 to 3. The
overall glomerular damage was expressed as the sum of the
above parameters, being scored from 0 to 9.
Immunofluorescence microscopy. Specimens snap-frozen
with dry ice, and aceton were cut by cryostat into 4 es-thick
sections. They were stained with FITC-labelled rabbit anti-
mouse IgG, C3 or 1gM (Cappei) and examined under fluores-
cence. The intensity of fluorescence in the mesangial and
peripheral capillary areas was separately evaluated and each
graded into negative fluorescence, weak, moderate or intense
fluorescence, which were scored 0, 1, 2, and 3, respectively.
Accordingly, the glomerular lesion was graded from 0 to 6.
Statistics
Statistical analyses were done using Student's t-test and
Fisher's exact test, where appropriate. Data were expressed as
mean 1 SE throughout the text.
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Table I. Effect of 15-dsp on the mean body weight and the life span of B/WFI mice
Dose of 15-dsp mg/kg body WI, every 1wo days
0 0.6 1.5 3.0 6.0
No. ofmice 10 ii 10 11 10
Mean body weight, g
(no. of mice surviving)
14 weeks of age 35 0.9 31 0.7a 36 1.5 35 0.7 32 0.5C
(10) (11) (10) (11) (10)
20 weeks of age 35 0.8 33 1.1 38 1.3 37 1.0 34 0.5
(10) (11) (10) (11) (10)
30 weeks of age 41 1.1 39 1.1 39 1.3 38 0.8 33 0.7k
(9) (11) (10) (Ii) (10)
40 weeks of age 33 2.6 40 1.6 42 l.2 41 l.2 33 0.6
(6) (10) (10)" (11)" (10)"
Soweeksofage 38 41 1.6 45±1.2 43±1.1 35
(2) (10)" (10)" (11)" (10)"
60 weeks of age 28 3.3 39 l.9 47 1.8a 45 o9 36 0.7
(2) (7) (10)" (Ii)" (9)b
70 weeks of age / 39 1.5 48 2.8 47 1.1 37 0.9
(0) (5)b (JØ)b (11)" (9)"
Mean survival 43 3.6 >62 >70 >70 >69
weeks of age
a P < 0.05 vs. control mice of the same ageb P < 0.05 vs. control by Fisher's exact test
Table 2. Effect of 15-dsp on spleen weight and IL-2 production
Age of mice weeks
14 20 24 28 32 36
Spleen weight mg
Control mice 116 6.8 110 4.0 171 21.8 188 16.2 246± 31.5 319±29.1
(1V) (10)
15-dsp treated mice
(10) (10) (8)
110 3.0 109 5.1C 110 47b
(8)
100 3.6"
(6)
109 4.6"
(AT) (II) (10) (9) (10) (10)
IL-2 produced U/mi
Control mice 3.1 0.56 8.4 2.98 2.7 0.20 3.6 0.54
(N) (3) (4) (5) (5)
15-dsp treated mice 34.4 8.50' 8.4 1.28" 5.0 1.74
(IV) (4) (5) (5)
a Number of mice studied
b P < 0.01
P< 0.05 vs. control mice by Student's f-test (after logarithmic transformation, where appropriate)
Results
The percent survival of 50 to 70 weeks of age in mice treated
with 0.6, 1.5, 3.0 or 6.0 mg 15-dsp since 14 weeks of age was
significantly different compared with that in the control group of
mice, except that at 60 weeks of age in 0.6mg group (P < 0.05,
Fisher's exact test, Table 1). The mean survival of the control
group was 43 3.6 weeks (N = 10), while those in 0.6, 1.5, 3.0
and 6.0mg groups were >62, >70, >70 and >69 weeks of age,
respectively (Table 1). The average body weight of the 6 mg
15-dsp group was significantly decreased just prior to the start
of the therapy at 14 weeks [32 0.5 (SE) g] and also during the
therapy at 30 weeks of age (33 0.5 g) compared with the
respective, same-aged control group of mice (35 0.9 g and 41
1.1 g), although the treated mice were behaving normally
with no other clinical abnormalities. Likewise, the mean body
weight of the 0.6 mg group of mice was significantly lower at the
start of therapy (31 0.7 g), but subsequent catch-up growth
was observed. On the other hand, the weight of the 0.6, 1.5 and
3.0mg groups significantly increased compared with the control
group at 40 weeks of age when 40% of the control group of mice
were already dead due to nephropathy (P < 0.01, Table 1). The
dose of 6 mg was chosen for the subsequent experiments
concerning the drug effect on the development of nephropathy.
Age-dependent splenomegaly as well as the increase in the
total spleen cell number observed at 24 weeks or later in the
control mice was completely suppressed in the treated mice
(Table 2 and Fig. 1). Likewise, L3T4+ splenocytes in the
15-dsp group significantly decreased in number at 24 weeks of
age or later compared with the control group (Fig. 1), although
the proportions of L3T4+ and Lyt2+ cells were maintained at
the level comparable with those of the young mice before onset
of the illness, and their L3T4+/Lyt2+ ratios at 20, 24 and 32
weeks of age were lower than those of the same aged control
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peripheral capillary loops. In contrast, the effect of the drug on
1gM deposition, which was mostly present in the mesangeal
area, was shown only to be marginal (Fig. 4).
Discussion
Spergualin was originally extracted and purified from the
culture filtrate of a bacillus strain, BMG 162-aF2, closely related
to Bacillus laterosporus, which was isolated from a soil sample
collected at Ohira-san, Tochigi Prefecture [81. It is easily
soluble in water and the solution is stable at 5°C for one week.
Only 6.25 p.g/ml of spergualin inhibited the growth of B. subtilis,
PC1219, S. aureus Smith, Sal typhi T-63 and Pr. vulgaris 0X19.
In mice which were intraperitoneally inoculated with io L-12l0
leukemia cells, daily i.p. injection of spergualin, 1.56 to 50
mg/kg for nine days, prolonged their survival. (—)15-Deoxy-
spergualin, one of its major derivatives, showed about eight
times stronger inhibition against L-l2lO cells, and its clinical
trial on leukemic patients are in progress with promising interim
results. In addition, a potent immunosuppressive action was
later shown to be one of the major pharmacological features
inherent to spergualin and its derivatives [12, 131. The survival
of heterotopically-allotransplanted rat thyroid [17] or heart [18,
19] was significantly prolonged by 15-dsp, and the induction of
allospecific suppressor cells or tolerance was suggested [18, 19].
In rat, active Heymann nephritis [20], serum anti-Fx1A anti-
body production and the recognition of nephritis-related anti-
gens was inhibited by the drug, which was intraperitoneally
administered since the time of the initial immunization. In
murine lupus model, Makino et al [211 showed that in male
BXSB and MRL/lpr mice 15-dsp suppressed the development
of immunological abnormalities, such as increased IgG-PFC
production by their splenocytes and the onset and the progres-
sion of lupus nephritis. In the present report on New Zealand
black/white Fl mice, we showed that 15-dsp resulted in the
decrease in serum IgG anti-ds DNA level and in glomerular
deposition of IgG and C3, along with marked prolongation of
over 30 weeks of their life span. The above data taken together,
we may say that 15-dsp effectively suppresses polyclonal acti-
vation of lymphocytes common to these lupus prone mice [4,
22] and inhibits the development of nephropathy. To determine
if the drug is also effective for on-going nephropathy, B/WFI
mice were treated with 15-dsp from 28 to 40 weeks of age; these
mice showed suppression of splenomegally and a decrease in
proteinuria (manuscript in preparation). These results may
point to the ultimate clinical utility of the drug, although the
present study alone does not permit any conclusion concerning
the human use of 15-dsp.
Compared with LD50 dosage of 47.0 mg/kg body weight of
15-dsp, s.c., in 5-week-old female ICR mice [11], the dose of 6.0
mg/kg, s.c., every other day employed by us is less than 1/13
LD50. The dose may be safe and appropriate considering the
good clinical condition of the animals and the significantly-
prolonged life span of the treated animals compared with the
control mice. Additionally, the tissue specimen obtained from
the treated mice at 32 weeks of age showed no manifest
pulmonary involvement, which was reported to be present in
rats and dogs given large doses of the drug for three months.
However, it was later shown that lower doses such as 0.6, 1.5
and 3.0 mg/kg were also effective in prolonging the survival of
B/WF1 (Table 1). Accordingly, the minimal effective dose of the
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Fig. I. Effect of 15-dsp on the numbers of total spleen cells, on the
total numbers and percentage of L3T4+ and Lyt2+ cells and on the
ratio of L3T4+/Lyt2+ cells. Closed circle represents mean value of the
control mice; open circle: that of 15-dsp-treated mice. Vertical bar
represents I SE. < 0.01; < 0.05 vs. the same-aged control mice.
mice. In contrast, IL-2 production in the treated mice was
significantly higher at 20 and 28 weeks of age than that in the
control mice (P < 0.05 and <0.01, respectively; Table 2).
Serum IgG anti-ds DNA antibody level, which significantly
increased at 24 weeks or later in the control mice, was main-
tained low by the 15-dsp administration (P < 0.01 vs. age-
matched control mice at 24 through 36 wks of age, Table 3). The
incidence of significant proteinuria (100 mg/dl or more) in the
15-dsp group was significantly lower at 32 and 36 weeks of age
compared with the control group (P < 0.001, Fisher's exact
test; Table 3).
Glomerular intracapillary proliferation in the control mice
increased with aging of the animals until 28 weeks, then it was
taken over by other lesions such as tuft necrosis and epithelial
crescent formation, On the other hand, the development of the
above histological lesions was totally suppressed by the 15-dsp
therapy, as may be seen from the significantly lower intracapil-
lary and total scores in the latter group at 24 weeks of age or
later (P < 0.01, Figs. 2 and 3). Glomerular deposition of mouse
IgG and C3 was likewise suppressed by the treatment at 24
through 36 weeks (P < 0.01, Figs. 4 and 5). It should be noted
that the decrease of these deposits was most evident in the
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Table 3. Effect of 15-dsp on serum IgG anti-ds DNA antibodies and incidence of significant proteinuria
Age of mice weeks
14 20 24 28 32 36
DNA binding activity cpm
Control mice 117± 31.4 126 76.8 632 167.5 523 129.6 1001 360.0 1011 223.0
(N)4 (11) (10) (10) (8) (8) (6)
15-dsp treated mice 121 43.4 113 39•4b 85 573b 112 19.71 87 27.6"
(I'J) (11) (10) (8) (10) (11)
Incidence of proteinuria  100 mg/dI %
Control mice 0 0 27.3 25.0 85.7 100
15-dsp treated mice 0 0 0 11.1 OC OC
a Numberof mice studied
b p < 0.01 vs. control mice by Student's (-test after logarithmic transformation
P < 0.001 vs. control mice by Fisher's exact test
Fig. 2. Effect of 15-dsp on glomerular histological score by light
microscopy. The degree of intracapillary proliferation, extracapillary
proliferation and tuft necrosis was each graded from 0 to 3 as described
in the text. Total glomerular score represents total of the above three
parameters. *p < 0.01 vs. control mice.
drug may be much lower than 6.0 mglkg. Also, it has to be noted
that the average body weight of the 6.0 mg group was signifi-
cantly lower at 30 weeks of age compared with the control
group of mice. As was previously observed by Izui et al [23],
drug toxicity and poor caloric intake may have delayed the
development of renal lesion and prolonged the life span of
B/WF1 mice. To exclude this possibility, our data on the 6 mg
group of mice may have to be critically re-evaluated using a
lower dose of the drug, although the survival of the mice was
prolonged to a comparable degree in all of the dosage groups
studied (0.6, 1.5, 3.0 and 6.0 mg groups, Table 1), whether or
not their body weight was decreased (clinical as well as immu-
nological studies in mice on lower doses to be reported). There
was no evidence obtained concerning tumor induction due to
the drug, although we observed infrequent tumor formation in
long-surviving B/WF1 mice on 15-dsp treatment. Among other
complications due to the drug may be cited anemia and
leukocytopenia in mice and anorexia, anemia, leucocytopenia
and liver dysfunction in rats and dogs, as observed by Aoyagi et
al (unpublished data). B/WF1 mice given 6.0 mg/kg/every two
days showed mild leukopenia. Balb/c mice given 1.5 to 3.0
mg/kg, s.c., of the drug daily for two months showed decrease
in body weight and thrombocytosis together with anemia and
leucopenia [24]. In rats daily given 15-dsp, 4.0 mg/kg, i.p., for
two months, an increased level of serum transaminase and
treated mice. Although IL-2 production was significantly poten-
tiated due to the drug, consistent with the in vitro results in
normal mice by us [25] and others [28], spleen L3T4+ cells
decreased in number in B/WF1 mice treated with 15-dsp. This
discrepancy may be caused by a selective action of the drug on
TH-2 subset of L3T4+ cells, which may dominate the spleen
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alkaline phosphatase and a decrease in liver weight were
observed, while dogs treated with 15-dsp, 0.3 mg/kg/day, i.v.,
for 91 days showed no abnormalities in hepatic function tests or
in liver weight (Aoyagi et al, unpublished observations). They
also showed that following intravenous injection to rats of
15-dsp labelled with 3H or '4C, almost all radioactivity was
measured in the urine within 24 hours. However, no renal
dysfunction due to 15-dsp has been reported. Teratogenesis in
fetal rats was not observed when their mothers were treated
0 , with 15-dsp, 4 mg/kg/day, i.v., for 11 days.
14 20 24 28 30 36 To study the mode of immunological action of 15-dsp to
Age, weeks suppress the humoral antibody production, we investigated the
effect of the drug on PFC generation in Balb/c mice [25]. PFC
production against both T-dependent and T-independent anti-
gens, such as TNP-keyhole limpet hemocyanin and TNP-
Brucella abortus, was inhibited by in vitro 15-dsp, as is the case
with mizoribine [26, 27] and in contrast to cyclosporin A [27],
which solely inhibited the PFC response against the T-depen-
dent antigen. The induction of suppressor cells [18] may be
important in the modulation of humoral antibody production
and suppression of the glomerulonephritis in B/WF1 mice, since
the proportion of L3T4+/Lyt2+ cells was maintained low in the
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Fig. 3. Light microscopy of the glomerulus,
PAS staining, x400. Left glomerulus was
obtained from 32-week-old control mouse;
right one, from 32-week-old 15-dsp treated
mouse. Note that the glomerulus from the
control mouse was enlarged with mesangial
widening and proliferation, subendothelial
deposition of PAS-positive material, capillary
obliteration and tuft necrosis. On the other
hand, only mild mesangial expansion was
observed in the glomerulus from the treated
mouse.
14 20 24 28 32 36
Fig. 5. Immunofluorescence microscopy of the glomerulus, FITC-
labelled anti-IgG, x400. Left glomerulus was obtained from 32-week-
old control mouse; right one, from 32-week-old treated mouse. In the
control glomerulus, global deposition of IgG was shown in the mesan-
gial area and along the peripheral capillaries, where segmental pseudo-
linear pattern was also noted. In contrast, segmental mesangial depo-
sition of IgO was observed in the glomerulus from the treated mouse.
when B/WF1 mice have full-blown disease [29]. While these
cells, which predominantly produce B cell growth and differen-
tiation factors and not IL-2 [30], are preferentially depleted by
15-dsp, the remaining normal' T helpers, or TH-1 cells may
continue to produce IL-2. This possibility, as well as direct
action on B cells suggested by the above PFC data remains to
14 20 24 28 32 36 be critically evaluated.
Age, weeks
Fig. 4. Effect of 15-dsp on glomerular deposition of IgG, C3 and 1gM.
The intensity of immunofluorescence at mesangial area and along the
peripheral capillaries was each graded into absent (0), weak (I),
moderate (2) or intense (3) staining. P < 0.01 vs. control mice.
6
5
4
3
2
5
C3
4
2
0
1gM
0
Acknowledgments
A part of the study was reported at the 10th International Congress of
Nephrology, London, 1987. This work was partly supported by a
grant-in-aid for New Drug Development Research from the Ministry of
Health and Welfare, Japan. Staphylococcal enterotoxin A used in this
Okubo et a!: Effect of15-dsp on murine lupus nephropathy 473
study was a gift from Dr. H. Igarashi, Tokyo Metropolitan Research
Institute of Hygiene, Tokyo, Japan. Technical assistance of Miss Rieko
Hara, Department of Pathology, and Mr. Masanobu Mizukoshi,
Kitasato Biochemical Laboratories was greatly appreciated.
Reprint requests to Michihito Okubo, Department of Medicine,
Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara,
Kanagawa-228, Japan.
References
1. AUSTIN HA, KLIPPEL JH, BALOW JE, LERICHE NGH, STEINBERG
AD, PLOTZ PH, DECKERJL: Therapy of lupus nephritis. Controlled
trial of prednisone and cytotoxic drugs. N Engi J Med 314:614—619,
1986
2. JONES MG, HARRIS G: Prolongation of life in female NZB/NZW
(Fl) hybrid mice by cyclosporin A. C/in Exp Immunol 59:1—9, 1985
3. MOUNTZ JD, SMITH HR, WILDER RL, REEVES JP, STEINBERG AD:
Cs-A therapy in MRL-lpr/lpr mice: Amelioration of immunopathol-
ogy despite autoantibody production. J Immunol 138:157—163, 1987
4. DUETMES M, FOURNIE GJ, MIGNON-CONTE M, IN S, CONTE JJ
Prevention of lupus diseases in MRL/1, NZBxNZW, and BXSB
mice treated with a cyclophosphazene derived drug. Clin Immunol
Immunopathol 41:193—205, 1986
5. KAMATA K, OKUBO M, UCHIYAMA T, MASAKI Y, KOBAYASHI Y,
TANAKA T: Effect of mizoribine on lupus nephropathy of New
Zealand Black/White Fl hybrid mice. C/in Immunol Immunopatho/
33:31—38, 1984
6. OKUBO M, KANEKO Y, MIZUKOSHI M, IN0UE K, SATO N,
KAMATA K, CHEN X-M, UCI-IIDA H, ENDO T: Decreased inter-
leukin 2 production and increased Leu 2a-positive suppressor cells
in renal transplant patients on triple therapy with mizonbine,
cyclosporine A, and prednisolone. Transplant Proc 19:1940—1943,
1987
7. CALNE RY, THIRU 5, MCMASTER P: Cyclosporine A in patients
receiving renal allografts from cadaver donors. Lancet 2:1323—
1327, 1978
8. TAKEUCHI T, IINUMA H, KUNIMOTO S, MASUDA T, ISHIZUKA M,
TAKEUCHI M, HAMADA M, NAGANAWA H, KONDO 5, UMEZAWA
H: A new antitumor antibiotic, spergualin: Isolation and antitumor
activity. J Antibiotics 34:1619—1621, 1981
9. UMEZAWA H, K0ND0 5, IINUMA H, KLJNIMOTO 5, IKEDA Y,
IwASAwA H, IDEDA D, TAKEUCHI T: Structure of an antitumor
antibiotic, spergualin. J Antibiotics 34:1622—1624, 1981
10. KONDO S, IWASAWA H, IKEDA D, UMEDA Y, IKEDA Y, IINUMA H,
UMEZAWA H: The total synthesis of spergualin, an antitumor
antibiotic. J Antibiotics 34:1625—1627, 1981
11. IWASAWA H, KONDO S, IKEDA D, TAKEUCHI T, UMEZAWA H:
Synthesis of (—)-l5-deoxyspergualin and (—)-spergualin-15-phos-
phate. JAntibiotics 35:1665—1669, 1982
12. TABIRA T: Development of therapeutic agents for autoimmune
encephalomyelitis. Suppressive effect of 15-deoxyspergualin on
acute experimental allergic encephalomyelitis in rat (2nd Report).
Jpn Ministry of Welfare annual report on development of therapeu-
tic agents for autoimmune diseases, 1986, pp. 43—50
13. I5HIZUKA M: Immunomodulation by spergualin. Jpn Ministry of
Welfare annual report on development of therapeutic agents for
autoimmune diseases, 1985, pp. 43—46
14. UCHIYAMA T, KAMAGATA Y, WAKAI M, Y05HI0KA M, FUJIWARA
H, IGARAsHI H: Study of the biological activities of toxic shock
syndrome toxin-l. I. Proliferative response and interleukin 2 pro-
duction by T cells stimulated with the toxin. Microbiol Immunol
30:469—483, 1986
15. UCHIYAMA T, KAMAGATA Y, YAN X-J, KOHNO M, YOSHIOKA M,
FUJIWARA H, IGARASHI H, OKUBO M, AWANO F, SAITO-KAKI T,
NAKANO M: Study of the biological activities of toxic shock
syndrome toxin-l: II. Induction of the proliferative response and
the interleukin 2 production by T cells from human peripheral blood
mononuclear cells stimulated with the toxin. C/in Exp Immunol 68:
638—647, 1987
16. SEKIGAWA I, ISHIDA Y, HIROSE 5, SAT0 H, SHIRAI T: Cellular
basis of in vitro anti-DNA antibody production: Evidence for T cell
dependence of IgG-class anti-DNA antibody synthesis in the
(NZBxNZW) Fl hybrid. J Immunol 136:1247—1252, 1986
17. MASAKI Y, INOUE K, SAT0 N, KAMATA K, OKUBO M, UCHIDA H,
SASAKI K, AOYAGI T: Immunosuppressive effect of (—)-15-deoxy-
spergualin on thyroid allograft in mice. Jpn J Transpl 23:35—42,
1988
18. SAKAKIBARA I, SuzuKI S, WATANABE H, AMEMIYA H: Analysis of
immunological tolerance by 15-deoxyspergualin (DSG) in heart-
transplanted rat. (abstract) Proc Jpn Soc immunol 17:625, 1987
19. Suzuiu S, KANASHIRO M, AMEMIYA H: Effect of a new im-
munosuppressant, 15-deoxyspergualin, on heterotopic rat heart
transplantation, in comparison with cyclosponne. Transpl 44:483—
487, 1987
20. SAT0 N, KAMATA K, OKUBO M: Treatment of Heymann nephritis
(HN) by 15-deoxyspergualin (SP) (abstract) Am Soc Nephrol 20th
Ann Meet, 1987
21. MAKINO M, FUJI WARA M, AOYAGI T, UMEZAWA H: Immunosup-
pressive activities of deoxyspergualin. 1. Effect of the long-term
administration of the drug on the development of munne lupus.
Immunopharmacol 14:107—114, 1987
22. Izul 5, MCCONAHEY PJ, DIXON FJ: Increased spontaneous poly-
clonal activation of B lymphocytes in mice with spontaneous
autoimmune disease. J Immunol 121:2213—2219, 1978
23. IZUI S, FERNANDES G, HARA I, MCCONAHEY PJ, JENSEN FC,
DIXON FJ, GOOD RA: Low-calorie diet selectively reduces expres-
sion of retroviral envelope glycoprotein gp7O in sera of NZBxNZW
F! hybrid mice. JExp Med 154:1116—1123, 1981
24. OKUBO M, KAMATA K, SATO N, MASAKI Y, UMETANI N, INouE
K, ZHANG H: Subacute toxicity of l5-deoxyspergualin in Balb/c
mice. Jpn Ministry of Welfare annual report on development of
therapeutic agents for autoimmune diseases, 1987, pp. 115—123
25. OKUBO M, INOUE K, UMETANI N, SATO N, KAMATA K, MASAKI
Y, MIZUKOSHI M, KOIDE A, UCHIYAMA T: Immunosuppressive
effect of l5-deoxyspergualin (15-dsp) in female New Zealand Black/
White Fl mice (B/W Fl). (1) Study on spleen cells. (abstract) Jpn
Soc Nephrol 30th Ann Meet 1987, p. 191
26. OKUBO M, CHEN X-M, KAMATA K, MASAKI Y, UCHIYAMA T:
Suppressive effect of mizonbine on humoral antibody production in
DBA/2 mice.. Transpi 41:495—498, 1986
27. OKuBo M, CHEN X-M, KAMATA K, MASAKI Y, UCHIYAMA T:
Immunosuppressive effect and mode of action of cyclosporin A (Cy
A) and mizoribine (MZR) on humoral immune response in mice.
Jpn J Nephrol 28:51—59, 1986
28. IsI-uzuKA M: Immunomodulation by spergualin. Jnp Ministry of
Welfare annual report on development of therapeutic agents for
autoimmune diseases, 1986, pp. 37—42
29. ANDO DG, SERCARZ EE, HAHN BH: Mechanisms of T and B cell
collaboration in the in vitro production of anti-DNA antibodies in
the NZB/NZW Fl murine SLE model. Jlmmunol 138:3185—3190,
1987
30. HERRON LR, COFFMAN RL, KOTZIN RL: Enhanced response of
autoantibody-secreting B cells from young NZB/NZW mice to
T-cell-derived differentiation signals. C/in Immunol Immunopathol
46:314—327, 1988
